FY2024 EPS Estimates for Shattuck Labs Cut by HC Wainwright

Shattuck Labs, Inc. (NASDAQ:STTK) – Research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Shattuck Labs in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($1.54) per share for the year, down from their previous estimate of ($1.41). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

Several other research firms also recently commented on STTK. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Finally, Citigroup downgraded Shattuck Labs from a “buy” rating to a “neutral” rating and cut their price objective for the company from $8.00 to $2.00 in a report on Wednesday, October 2nd. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Shattuck Labs presently has a consensus rating of “Hold” and an average target price of $8.67.

Shattuck Labs Trading Down 10.5 %

NASDAQ STTK opened at $1.11 on Monday. The company has a market cap of $52.74 million, a PE ratio of -0.72 and a beta of 1.85. Shattuck Labs has a 12 month low of $1.07 and a 12 month high of $11.76. The stock has a 50 day moving average of $2.03 and a 200-day moving average of $4.12.

Institutional Investors Weigh In On Shattuck Labs

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its position in Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after buying an additional 150,340 shares during the period. Vanguard Group Inc. increased its position in Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after buying an additional 502,860 shares during the period. Virtu Financial LLC bought a new position in Shattuck Labs during the 1st quarter worth $113,000. American Century Companies Inc. increased its position in Shattuck Labs by 25.4% during the 2nd quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock worth $183,000 after buying an additional 9,608 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Shattuck Labs during the 2nd quarter worth $170,000. Institutional investors own 58.74% of the company’s stock.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber purchased 36,500 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the purchase, the chief executive officer now owns 71,002 shares in the company, valued at approximately $85,912.42. The trade was a 105.79 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 10.50% of the stock is owned by company insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.